Healthcare Industry News: migraine
News Release - October 15, 2007
Sepracor Announces Senior Management Appointments as Part of Commercial Re-OrganizationMARLBOROUGH, Mass.--(HSMN NewsFeed)--Sepracor Inc. (NasdaqGS: SEPR ) today announced the appointment of several senior managers to key strategic and operational roles within the commercial function of the organization. Mark Iwicki has been appointed to the newly created position of Executive Vice President and Chief Commercial Officer, Jay Smith has been appointed to the position of Senior Vice President of Sales, Dean Giovanniello has been appointed to the position of Vice President of Marketing and Thomas Hoover has been appointed to the position of Vice President, New Products Planning.
“I am pleased to announce the addition of such accomplished professionals to our commercial leadership team at Sepracor,” said Adrian Adams, President and Chief Executive Officer. “Mark brings with him a wealth of successful sales and marketing, operational and general management experience, and his energy and leadership skills will be instrumental to the growth of our current and future product franchises. In addition to Mark, the appointments of Jay, Thomas and Dean support our plans to deepen and broaden our management team’s strengths and capabilities and reinforce our objective to deliver enhanced performance and productivity across our commercial organization. This is a key component of our plan and vision for growth for Sepracor.”
Mr. Iwicki joins Sepracor from Novartis where he was Vice President, Cardiovascular Business Franchise Head. Mr. Iwicki led the U.S. cardiovascular franchise, which is the single largest business unit in Novartis, generating annual sales of over $4 billion. This franchise includes products such as DIOVAN®, LOTREL®, TEKTURNA®, EXFORGE® and STARLIX®. Under Mark’s leadership, the cardiovascular business went from a declining market share position to regaining and sustaining market share and growth. During his career at Novartis, Mark held many senior positions including Vice President, Business Franchise Head, which oversaw several product franchises, including ZELNORM®, FAMVIR®, and MIACALCIN® and a portfolio of hormone replacement therapy products. Prior to his tenure with Novartis, Mr. Iwicki served in sales, marketing and management positions at Astra Merck Inc. and began his career at Merck & Co.
Mr. Smith joins Sepracor from Novartis where he served as National Vice President of Sales and Head of Cardiovascular Innovations Marketing. Mr. Smith led the national primary care and specialty field sales forces, which generate annual sales of over $3.5 billion from products such as DIOVAN, DIOVAN/HCT®, LOTREL, TEKTURNA, EXFORGE and STARLIX. In this position, he had leadership responsibility for over 1,200 sales professionals, a team that consistently achieved number one customer rankings in industry surveys. Additionally, in this role, Mr. Smith oversaw the cardiovascular innovations marketing team at Novartis and was instrumental in creating and implementing patient and customer-centric programs like the BP Success Zone. Jay began his career at Johnson & Johnson where he served in various sales and marketing roles.
Mr. Giovanniello joins Sepracor from GlaxoSmithKline where he most recently held the position of Executive Director of Marketing for the company’s migraine products, which generate annual sales of approximately $1.3 billion. Dean’s career with GlaxoSmithKline spanned eighteen years during which time he achieved progressively advanced leadership positions in sales and marketing and hands-on experience with large existing franchises, new product launches, in-licensing and life-cycle management in many primary care and specialty therapeutic areas, including central nervous system, gastroenterology, oncology, HIV and anti-infectives.
Mr. Hoover joins Sepracor from GlaxoSmithKline where he served as Therapy Area Head, Business and Commercial Analysis in the Global Commercial Strategy division. In this role, he was responsible for delivering strategic, commercial and financial insight into an extensive portfolio of therapeutic areas and projects within research and development. Prior to this role, he served as Director, Business and Commercial Analysis, Cardiovascular, Metabolic and Urology. Prior to his career at GlaxoSmithKline, he served as a Project Leader at The Boston Consulting Group.
Sepracor Inc. is a research-based pharmaceutical company dedicated to treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products that are directed toward serving unmet medical needs. Sepracor’s drug development program has yielded a portfolio of pharmaceutical products and candidates with a focus on respiratory and central nervous system disorders. Sepracor’s corporate headquarters are located in Marlborough, Massachusetts.
This press release contains forward-looking statements that involve risks and uncertainties, including statements with respect to enhanced performance and productivity across Sepracor’s commercial organization; and the expected growth of Sepracor’s current and future product franchises and its business. Among the factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: Sepracor’s ability to successfully achieve innovative and value-enhancing corporate development and licensing initiatives and other growth opportunities; unexpected delays in the commercial availability of Sepracor’s products; the results of clinical trials with respect to products under development; the timing and success of submission, acceptance and approval of regulatory filings; the clinical benefits and commercial success of Sepracor’s products; the scope of Sepracor’s trademarks, patents and the patents of others and the success of challenges by others of Sepracor’s patents and trademarks; the ability of the Company to attract and retain qualified personnel; the performance of Sepracor’s licensees and other collaboration partners; the availability of sufficient funds to continue research and development efforts; and certain other factors that may affect future operating results and are detailed in Sepracor’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2007 and other periodic filings that Sepracor has made with the Securities and Exchange Commission. Sepracor disclaims any intention or obligation to update any forward-looking statements as a result of developments occurring after the date such statement was first made.
Diovan, Diovan/HCT, Lotrel, Zelnorm, Tekturna, Famvir, Miacalcin, and Exforge are registered trademarks of Novartis AG Corporation or its affiliate. Starlix is a registered trademark of Sandoz AG Corporation.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.